Ivabradine: Indications, Dosing, Contraindications, and Monitoring
Ivabradine is indicated specifically for chronic heart failure with reduced ejection fraction (HFrEF ≤35%) in patients with sinus rhythm and heart rate ≥70 bpm who are on maximally tolerated beta-blockers or have beta-blocker contraindications, but it is NOT recommended for chronic coronary syndrome patients with preserved ejection fraction (>40%) without clinical heart failure. 1
Primary Indications
Heart Failure with Reduced Ejection Fraction (Class IIa, Level B-R)
Ivabradine reduces hospitalization risk in patients meeting ALL of the following criteria 2, 1:
- LVEF ≤35%
- Stable, symptomatic chronic HF (NYHA class II-III)
- Sinus rhythm with resting HR ≥70 bpm
- On maximally tolerated beta-blocker doses (this is critical—only 25% of SHIFT trial patients were on optimal beta-blocker doses, and beta-blockers have proven mortality benefits that ivabradine lacks) 2
- OR have beta-blocker contraindication/intolerance
Chronic Coronary Syndrome with LV Dysfunction
Ivabradine should be considered as add-on antianginal therapy specifically in patients with **LVEF <40%** and inadequate symptom control 3. This is a narrow indication—the drug is explicitly **NOT recommended** for CCS patients with LVEF >40% and no clinical heart failure, as the SIGNIFY trial showed no benefit and potential harm in this population 3, 4.
Dosing Regimen
Standard Adult Dosing 1
- Starting dose: 5 mg twice daily with food
- Assess after 2 weeks and adjust based on resting heart rate:
- HR >60 bpm: Increase by 2.5 mg twice daily (maximum 7.5 mg twice daily)
- HR 50-60 bpm: Maintain current dose
- HR <50 bpm or bradycardia symptoms: Decrease by 2.5 mg twice daily; discontinue if already on 2.5 mg twice daily
High-Risk Patients 1
For patients with conduction defects or those where bradycardia could cause hemodynamic compromise:
- Start at 2.5 mg twice daily
- Titrate more cautiously based on heart rate response
Target Heart Rate
Aim for 50-60 bpm at rest 1
Absolute Contraindications 1
Ivabradine is contraindicated in:
- Acute decompensated heart failure
- Clinically significant hypotension
- Sick sinus syndrome, sinoatrial block, or 3rd-degree AV block (unless functioning demand pacemaker present)
- Clinically significant bradycardia
- Severe hepatic impairment
- Pacemaker dependence (HR maintained exclusively by pacemaker)
- Concomitant strong CYP3A4 inhibitors (ketoconazole, clarithromycin, nefazodone, ritonavir, nelfinavir)
Critical Warnings and Precautions
Atrial Fibrillation Risk 1
Ivabradine increases atrial fibrillation risk (5.0% vs 3.9% per patient-year in SHIFT). Regularly monitor cardiac rhythm and discontinue if atrial fibrillation develops 1.
Bradycardia and Conduction Disturbances 1
- Bradycardia occurred in 6.0% per patient-year (2.7% symptomatic) in SHIFT
- Risk factors include sinus node dysfunction, conduction defects (1st or 2nd-degree AV block, bundle branch block), ventricular dyssynchrony
- Not recommended in 2nd-degree AV block 1
Drug Interactions 3, 1
- Avoid combination with non-dihydropyridine calcium channel blockers (verapamil, diltiazem) or other strong CYP3A4 inhibitors 3
- Use caution with other negative chronotropes—monitor heart rate closely 1
Fetal Toxicity 1
Advise females of reproductive potential to use effective contraception—embryo-fetal toxicity and cardiac teratogenic effects occurred in animal studies at 1-3 times human exposure 1.
Monitoring Recommendations
Initial Monitoring
- Baseline resting heart rate (must be ≥70 bpm to initiate)
- Baseline ECG to assess rhythm and conduction
- Assess at 2 weeks for dose titration based on heart rate
Ongoing Monitoring
- Regular heart rate assessment at each visit
- Regular cardiac rhythm monitoring to detect atrial fibrillation 1
- Monitor for bradycardia symptoms: dizziness, fatigue, hypotension
- Adjust dose based on resting heart rate per algorithm above
Key Clinical Pitfalls
Do not use in preserved EF without HF: The SIGNIFY trial demonstrated potential harm in stable CAD patients with LVEF >40% without clinical heart failure—ivabradine actually increased the primary endpoint in patients with activity-limiting angina 4.
Optimize beta-blockers first: Ivabradine should only be added after maximizing beta-blocker therapy, as beta-blockers have proven mortality benefits that ivabradine lacks 2.
Monitor for atrial fibrillation: This is a class effect requiring vigilance and immediate discontinuation if it develops 1.
Avoid CYP3A4 inhibitors: Strong inhibitors are absolutely contraindicated; moderate inhibitors require caution 3, 1.